Skip to main content

Table 1 Demographics and Patient Information

From: Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series

Case

Age

Sex

Disease

ICI Therapy

Time to Presentation from ICI Initiation

Baseline Medical History

1

70

Male

Melanoma

Ipilimumab/Nivolumab

11 Days

Hypertension Colon Cancer

2

79

Male

Melanoma

Pembrolizumab

26 Days

CLL

3

61

Female

Breast Cancer

Durvalumab/Tremelimumab

28 Days

None

4

69

Male

Urothelial Carcinoma

Pembrolizumab

132 Days

CKD, Hypertension, Hyperlipidemia

Type 2 DM

CAD

5

67

Female

Melanoma

Ipilimumab/Nivolumab

14 Days

None

6

83

Male

Melanoma

Nivolumab, Adjuvant

31 Days

Hypertension,

Hyperlipidemia

Atrial fibrillation

7

70

Male

Renal Cell Carcinoma

Ipilimumab/Nivolumab

21 Days

Hypertension, CKD, Atrial Fibrillation

8

89

Male

Non-Small Cell Lung Carcinoma

Pembrolizumab

32 Days

Hypertension, Hyperlipidemia, CAD, CKD, Type 2 DM

  1. Baseline data, disease and treatment information for each patient. CLL chronic lymphocytic leukemia, CAD coronary artery disease, Type 2 DM type 2 diabetes mellitus, CKD chronic kidney disease